Venture Valuation and Biotechgate to participate in the 2026 BIO International Convention in San Diego
ZURICH, Switzerland, June 2026 – Venture Valuation and Biotechgate will participate in the 2026 BIO International Convention, taking place June 22–25, 2026, at the San Diego Convention Center, as well as the RESI Conference at the JULEP Venue in San Diego on June 22.
The team will be available at booth 2111 in the Swiss Biotech Pavilion, where attendees are invited to learn more about Venture Valuation’s independent valuation services, Biotechgate’s global life sciences database, and the company’s conference series. Registered attendees can also schedule one-on-one meetings with Venture Valuation and Biotechgate delegates through the conference portal.
In addition, Dr. Patrik Frei, Chief Executive Officer of Venture Valuation, and Dr. Gergely Iványi, Senior Consultant, will lead a workshop entitled “Product and Company Valuation” on June 21, 2026, at the San Diego Convention Center. The course will provide practical guidance on producing valuations for investment rounds, mergers and acquisitions, licensing transactions, and strategic decision-making in the life sciences industry.
Venture Valuation will also participate in RESI San Diego, a key event for any fundraising company. RESI connects early-stage life science and healthcare companies with investors and strategic partners from around the world, supporting fundraising and business development across drugs, devices, diagnostics and digital health.
The Biotechgate team will also be present at BIO International Convention to provide insights into its renowned business development and licensing database, including the newly launched AI Workspace feature, designed to help life science professionals identify opportunities, analyze companies and streamline partnering activities. Venture Valuations CEO, Patrik Frei, will be part of a Thematic Panel 5: “Supporting biotech innovation through regulatory collaboration” scheduled for Wednesday, 23rd June, from 2:30-3:15 pm at the European Pavillion (#2411).
About Venture Valuation:
Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology, medical technology, nanotechnology, renewable energies and information technology / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents. Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.
About Biotechgate:
Biotechgate is a leading business development and licensing platform for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 40,000 licensing deals and a clinical trials database containing over 1 million records from registries around the world.